A man had heart attack symptoms on a flight. A cardiologist and a pocket-sized tool on board may have helped save his life
Trad rushed over to the passenger who needed help to find a man drenched with sweat and complaining of chest pain. The man looked at the doctor and anxiously asked, 'am I going to die?'
'Not today,' Trad told the man.
He believed that the man in front of him was having a heart attack – pain the doctor was intimately familiar with after surviving one just last year.
Trad also knew he had the tools that might help save the man's life if it was a heart attack: medication and medical devices he had on him because he was flying home from a medical mission trip in Uganda with Cura for the World – an organization he founded that builds clinics in areas of need.
He also had a pocket-sized electrocardiogram, or ECG – something he never leaves home without after his own heart attack. The device, about the size of a credit card, would be a crucial tool in understanding the man's symptoms.
Now he just had to get to work.
It was three hours into the April 29 KLM flight to Amsterdam when Trad was thrust into emergency response mode.
The patient said that on a scale of one to 10, his chest pain was at a 10.
'Do we land right now?' Trad recalled the man's wife nervously asking.
Trad realized the first step was to calm down the Dutch couple, nearby passengers and flight crew.
'I think our training is so extensive that you almost get trained to be the captain of the ship and to calm everyone around you,' he said.
Trad then created a makeshift emergency room across a row of airplane seats, laid the man down with airplane pillows and propped his feet up to bring blood back to his heart.
After ruling out blood sugar and blood clot complications, the doctor used a 12-lead ECG from the medical mission trip to assess whether the man was having a heart attack. He quickly gave him five medications typically used to treat heart attacks.
Trad then used his personal ECG – an electrocardiogram that measures the heart's electrical activity – to help monitor the man's heart for abnormal beats, or arrhythmias. Trad has kept the device, a KardiaMobile card, in his wallet ever since his heart attack last year in case he has another cardiac event.
'The later manifestation of a heart attack is an arrhythmia. That's how people die,' Trad explained.
Although the 12-lead ECG was crucial to confirm the man was showing symptoms of a heart attack, the doctor said the card allowed him to continually monitor for arrhythmias in the three hours that followed.
The man put his thumbs on the card, and it transmitted data on his heart activity to Trad's app via Bluetooth.
Within 45 minutes after he took the medication, the man's chest pain and heart rate started to get better, the doctor said.
Trad's own heart attack had prevented him from going on his medical mission trip to Uganda in February 2024, leading him to go on a make-up trip that put him on the same plane as the man he helped save.
The doctor said his heart attack led to him being in the right place at the right time.
'I believe everything happens for a reason, I truly do,' he said.
During the ordeal, the pilot asked if they should divert the flight to Tunisia after speaking with the KLM on-ground physician, but Trad assured the crew that the patient was stable enough to make it to Amsterdam.
'We had a nurse that was taking his vitals every 10 to 15 minutes… and we had him hooked up to all these things… if we would have landed in Tunisia, they wouldn't have done anything differently other than obviously taking him to get a heart cath,' Trad said, referring to the catheterization procedure that allows doctors to examine or treat the heart and coronary arteries.
The man was stable throughout the remaining two hours of the flight. His chest pain returned as the plane was about to land, but additional medication resolved it, Trad said.
The man's wife told CNN that Trad and a nurse helped prevent her husband's condition from getting worse and did an 'unforgettable job.'
Once they landed, the man thanked the doctor and his wife hugged him 'very, very tight.'
'She said that you're our angel in the sky,' Trad recalled.
KLM told CNN the plane landed safely at Amsterdam Airport Schiphol, where an ambulance was waiting to take the man to a nearby hospital.
The man's wife said he is doing reasonably well considering the traumatic event. The hospital examined him for 12 hours and did not diagnose him with a heart attack, stroke or pulmonary embolism, she told CNN.
Trad believes this could be because of his timely treatment of the patient.
After having to cancel his Uganda trip last year because of his own heart attack, Trad said that helping save this man feels like a full circle moment for him.
He told the man it was a pleasure taking care of him and wished him the best before he ran to catch his connecting flight home.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a day ago
- Medscape
Are Probiotics Helpful in Treating Cardiovascular Issues?
As a primary care doctor, you're often the first clinician that patients trust to discuss cardiac issues. Not only can you assess cardiac symptoms, order diagnostic tests, and refer your patients to a cardiologist but also you can use this front-line role to discuss other ways to treat cardiac concerns. During your consultations, you will likely explain the role of healthier eating habits to boost cardiovascular health. If your conversations include using probiotics in a patient's diet there are specific things patients should know about probiotics and the impact on cardiovascular health. Do Probiotics Help Lower Cholesterol or Improve Circulatory Health? Probiotics may help the heart in ways we're just beginning to understand, said Maria Carolina Delgado-Lelievre, MD, assistant professor of medicine at University of Miami Miller School of Medicine, Miami. Clinical evidence demonstrates that certain strains of probiotics can reduce risk factors for heart disease, like high blood pressure, high cholesterol, and inflammation. For example, Delgado-Lelievre said, Lactobacillus and Bifidobacterium strains have been shown to reduce inflammatory markers, support better insulin sensitivity, and even help lower low-density lipoprotein (bad) cholesterol and triglycerides in some human and animal studies. 'One potential mechanism is through bile salt hydrolase activity — this helps break down bile in a way that reduces how much cholesterol is absorbed into the blood,' she said. In some cases, probiotics have also been linked to better blood flow, by helping remove cholesterol plaques in the arteries, she said. Best Ways for Patients to Consume Probiotics Delgado-Lelievre said that traditional and everyday foods are rich in natural probiotics. These include: Yogurt and kefir (fermented milk drinks) Cheese (certain aged varieties) Miso, tempeh, natto, idli, and dosa (fermented soy or grain-based foods) Sauerkraut, kimchi, pickles (naturally fermented) An effective approach could be to ease a patient to probiotics. 'I always recommend yogurt as a food to eat daily because it has protein and probiotics, mainly when people complain of gastrointestinal issues you can start by trying probiotics to see if they help,' said Sandra Arévalo, MPH, RDN, CDN, CDCES, FAND, a registered dietitian nutritionist and spokesperson for the Academy of Nutrition and Dietetics, who is director of Community Health and Wellness and administrative director of the Jacob's Family Pride Wellness Center at Montefiore Nyack Hospital in Nyack, New York. Should You Recommend a Probiotic Supplement? Probiotic supplements can be a good option, especially if someone doesn't eat many fermented foods. 'But not all products are equally effective, and not all strains work the same way,' cautioned Delgado-Lelievre. Because some probiotics are more geared toward gut health, while others may support heart or metabolic function, it's important to choose wisely, she said. Sandra Arévalo, MPH, RDN, CDN, CDCES, FAND She recommends patients discuss taking a probiotic supplement with a healthcare provider before starting any supplement, particularly if they have existing conditions like heart disease, diabetes, or are on medications. 'A tailored recommendation is often safer and more effective,' she said. Who Shouldn't Take or Eat Foods With Probiotics? In certain cases, patients should avoid them. While probiotics are generally safe for healthy people, caution is needed in those with weakened immune systems, such as patients undergoing chemotherapy, transplant recipients, or low birth weight infants. 'In rare cases, even nonpathogenic bacteria can lead to infections in vulnerable individuals,' Delgado-Lelievre said. Again, patients should speak to healthcare providers before starting probiotic supplements or even high-dose fermented foods. Antonette Hardie, RN It's widely known how probiotics can help regulate bowel movements, help reduce gas and inflammation, and reduce bloating, said Antonette Hardie, RN, a registered dietitian at Ohio State University Wexner Medical Center in Columbus, Ohio. But she cautioned, although 'highly unlikely,' there's always a thing as too much of anything, including probiotics. 'Too many probiotics can cause diarrhea, gas, and bloating while your body adjusts and these likely resolve within a few days or weeks,' Hardie said. Manage Expectations for Patients Although beneficial, explain to your patients that probiotics 'are not a magic pill, but they are a promising ally in cardiovascular health,' Delgado-Lelievre said. 'Through their impact on inflammation, blood pressure, cholesterol, and insulin sensitivity, they may help reduce risk factors for heart disease.' So whether through diet or supplements, she said the key is to help your patients make informed choices as probiotics are part of a broader lifestyle approach that puts prevention at the heart of care.
Yahoo
2 days ago
- Yahoo
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
Monica Seles - argenx 1 Monica Seles - argenx 2 Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the 'Go for Greater' MG patient support initiative at the 2025 U.S. Open Tennis Championships August 12, 2025 6:45 AM EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced a partnership with nine-time Grand Slam tennis champion Monica Seles. For the first time ever, Seles is publicly speaking out about her experience with myasthenia gravis (MG) in support of argenx's Go for Greater initiative. The partnership aims to raise awareness and understanding of MG, and connect those affected with available tools and support resources. 'My MG journey over the past 5 years has not been an easy one. I felt isolated and defeated as many of the activities I enjoyed were no longer physically possible for me. I've since realized that by sharing my story, I can raise awareness of this disease, empower patients to advocate for themselves and help them connect with the MG community for support,' said Monica Seles. 'I am excited to partner with the argenx team – to inspire others living with MG to rally against this disease, pursue their goals, and live a fulfilling life. We're all in this together.' 'At argenx, we are committed to supporting the MG community by fostering understanding and connection,' said Karen Massey, Chief Operating Officer, argenx. 'We applaud Monica for sharing her personal story and are excited to collaborate with her to amplify the voices of MG patients and caregivers. Her journey and dedication to this cause will help people living with MG engage in meaningful conversations and build a supportive network around this challenging disease. Together, we hope to shine a light of understanding and support for those affected by MG.' argenx has a long-standing commitment to the MG community, helping to empower patients through programs such as Go for Greater. This program supports patients in achieving a greater quality of living by fostering connections between real people with MG, and offering support and helpful resources. In addition to the new partnership with Seles, argenx is a premier Global sponsor of the upcoming 2025 U.S. Open to amplify awareness of MG on a global stage. In the U.S., over 120,000 people are living with MG, an autoimmune, neuromuscular condition that causes a variety of symptoms, including weakness in the arms and legs, fatigue, difficulty walking, and blurred and double vision. For more information about the Go for Greater campaign, visit About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. For further information, please contact: Media contact for argenx:Ben Petokbpetok@ Media contact for Real Chemistry: Ashley Cohen ascohen@ Attachments Monica Seles - argenx 1 Monica Seles - argenx 2Sign in to access your portfolio
Medscape
2 days ago
- Medscape
In Real World, Women More Likely to Have Issues With GLP-1s
If it weren't for post hoc analyses and findings from curious academic labs, the substantial list of biological differences that separates the sexes would still be relegated to the shadows. That list — including research from the fields of neurology, cardiology, immunology, oncology, endocrinology — shows that the longtime presumption of men and women reacting as one to diagnoses, disease progression, and treatment should be considered, scientifically speaking, passé. But in the world of clinical trials, it has been and still is mostly a sexless, homogenous world. One reason: Stratifying by sex in a trial would not be cheap. 'Doing that up front would cost millions more,' said Antonella Santuccione Chadha, MD, PhD, founder and CEO of the Women's Brain Foundation and a former member of the EU Commission Directorate-General for Health and Food Safety. A significant issue is under enrollment of women in randomized trials, meaning the percentage of women enrolled isn't in line with the percentage of women with a particular disease in the real world — so signals that indicate an adverse event are not picked up. From a systems perspective, women do not clear drugs through their kidneys as quickly as men, and women maintain a higher blood concentration of the medication. 'Women may be overmedicated,' Neurologist Irving Zucker and others wrote in a 2020 analysis of 86 medications. This can lead to adverse events (AEs). And they do. ' Women experience adverse drug reactions nearly twice as often as men, yet the role of sex as a biological factor in the generation of [these reactions] is poorly understood,' Zucker wrote in that study, published in the journal Biology of Sex Differences , which showed that pharmacokinetics 'strongly linked' sex differences in adverse drug events. Antonella Santuccione Chadha, MD, PhD Among the 86 medications was the GLP-1 receptor agonist (GLP-1 RA), liraglutide. It was found to be biased toward women with regard to headache, vomiting, nausea. There are little stratified data in the GLP-1 RA receptor clinical trials, let alone appropriate enrollment percentages, as compared to real world disease prevalence. Considering that these medications are being used in patients with diabetes, obesity and overweight, cardiovascular problems, and likely in the future, to mitigate Alzheimer disease advancement, it likely would help to know how sex affects these drugs. So the question is: How can general practitioners determine what treatment is right for patients, especially their female patients, when so little evidence is based on sex? 'The side effects are very real and important to track,' said Sadiya S. Khan, MD, MSc, professor of cardiovascular epidemiology, and associate professor, medicine medical social sciences, preventive medicine, at the Feinberg School of Medicine at Northwestern University, Chicago. 'The truth about GLP-1 agonists is that you have to personalize it for the patient in front of you,' said Martha Gulati, MD, MS, professor of cardiology at Cedars-Sinai Heart Institute. Efficacy has to be balanced with the potential for side effects. 'Every individual will be slightly different.' Sex Differences of Note In its natural state, GLP-1 is found in many areas of the body, including the brain. It has multiple purposes, including gastric emptying, food intake inhibition, and neuroprotective effects on lung and cardiovascular systems. But in its natural state, GLP-1 has a short half-life, hence the pharmaceutical drive for analogues. As a class, these analogues, primarily the injectables, have been much ballyhooed for their ability to treat diabetes, induce weight loss, and reduce the risk for cardiovascular events. One recent study also demonstrated how the GLP-1 RAs can mitigate cognition issues. These analyses show how the GLP-1 RAs work at the stratified population level: In this study, women, who generally have a smaller stature than men, had higher concentrations (32%) of the tested medication than men; patients with diabetes had lower amounts of medication than those with normal blood glucose levels or prediabetes. In a new analysis of FAERS, the FDA's adverse event reporting system, among reports of neurologic related events in GLP-1 agonists, 46.25% occurred within 30 days of the start of treatment. The report, based on complaints filed from 2004 to 2025, found that 11.58% of the 250,014 listed were neurologic in nature. Women reported 65% of the 28,953 neurologic AEs events; most came from consumers. The top AEs reported were dizziness, tremor, and dysgeusia. Women who had taken semaglutide, liraglutide, and tirzepatide reported 65% of the 372 psychiatric events found in the EudraVigilance database, between January 1, 2021, and May 30, 2023. In a new JAMA article discussing the management of GLP-1 events, neurologic issues are not mentioned, just common gastrointestinal ailments, including nausea. In the huge study published in February confirming semaglutide 2.4 mg safety in overweight, obesity, cardiovascular disease but not diabetes, the sexes were segregated in listing fractures, poisoning, and procedural events but not in serious cardiac and nervous system disorders. article discussing the management of GLP-1 events, neurologic issues are not mentioned, just common gastrointestinal ailments, including nausea. In the huge study published in February confirming semaglutide 2.4 mg safety in overweight, obesity, cardiovascular disease but not diabetes, the sexes were segregated in listing fractures, poisoning, and procedural events but not in serious cardiac and nervous system disorders. The inclusion criteria for the still-running Evoke trials, which is testing oral semaglutide's efficacy in early-stage symptomatic Alzheimer's disease (AD), have no breakdown of the 1840 participants by sex, either in or the peer-reviewed summary. AD affects women significantly more than men. Efforts to reach an investigator were not successful. With regard to diabetes, it seems the sexes have more differences than commonalities, according to a 2023 study in Diabetologia , the journal of the European Association for the study of diabetes. One review found men: are younger at diagnosis; have a lower BMI and a lower risk factor burden, including hypertension and more weight gain; have a lower relative risk for cardiovascular complications and death; and get guideline recommended care more than women. Sadiya S. Khan, MD, MSc 'Across their lifetime, changes in sex hormones mean that women experience greater variations in the risk of cardiometabolic disease, including type 2 diabetes,' the Austria-based authors wrote. A Danish study reviewing more than 200,000 cases in the country's national registry reached similar conclusions. A cause for concern: Population trends show that more women are obese or severely obese, particularly among those older than 60 years. Clinical Discussion Prescribing women GLP-1 RAs takes some planning, Gulati and Khan said. Conversations about what to expect are critical, especially about potential AEs. Gulati said women respond better to these medications, especially if they are premenopausal. These physicians, both preventive cardiologists, discuss the benefits, including lower hypertension, weight reduction, and better glycemic control. Advice includes eating small meals, avoiding greasy food, and eating lots of fiber because constipation is no fun. And patients have to be prepared for the side effects. 'I have this oatmeal spiel,' Gulati said. One patient, she said, insisted on eating greasy food until the AEs won out. 'She started improving her diet and she got the results she wanted…If they get something you told them about, they know more.' Gulati, president-elect of the American Society for Preventive Cardiology, said some women won't be able to go up to the highest dosage because of the AEs. Khan said the AEs increase as the GLP-1 RA dosage increases. She said that in real life, 80% of people taking a GLP-1 RA stop because of the side effects. 'It's about going slow and seeing if people can benefit.' At least one premarketing clinical study claimed that dose adjustment by sex wasn't necessary. Robert Kushner, MD, the lead investigator on the semaglutide obesity study, said in a JAMA podcast that more than 30% of patients, at least in the phase 3 trials, stopped using semaglutide because of nausea, constipation, diarrhea, and vomiting. His advice paired with that of Khan and Gulati. Most, if not all, of this conversation could be avoided if sex-based evidence was generated in preclinical research and then used to shape the trial, said Santuccione Chadha. By investing more money in the beginning of the trial to determine sex-based differences, there would be a 'higher return on investment across the chain.' There would be fewer side effects and more adherence to drugs, the GLP-1s included. But with the current method of research, 'What happens is that there are unexpected side effects, more adverse events in the female population, who also get more serious events.' Gulati agreed more planning is needed prior to trial enrollment. 'Honestly? I think it is because of a lack of prestudy planning. Who do we want, and where will we get them?' If the trial is underpowered, 'you can't look at sex differences.' The fact that the GLP-1 RAs have proven effective in so many body systems now has more specialists prescribing these medicines. Khan said interdisciplinary care is critical, so it's necessary to have a point person. 'We are realizing this, who is owning responsibility, who is comfortable with it.'
